biotech.today

Details

  • ●Modalities: antibodies
  • ●Therapeutic areas: oncology, immunology
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $75M

Partners & investors

  • Eli Lilly· Investor
  • a16z· Investor

Key considerations

  • ●AI tools in use: Milliner Platform
  • ●$75M Series B (2023)
  • ●a16z Bio + Health-backed
  • ●Eli Lilly partnership
Get live updates on BigHat Biosciences’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Mark DePristo

Co-Founder & CEO

ml-for-genomicsex-Google
Visit website →LinkedIn →